Find out more about how AI-processed CECT scans can improve the management of unresectable hepatocellular carcinoma.

Selective internal radiation therapy with yttrium-90 resin microspheres followed by lenvatinib plus PD-1 inhibitor for large or huge advanced-stage hepatocellular carcinoma: A retrospective cohort ...

For many patients, the path to a liver cancer diagnosis is not straightforward. Symptoms can be vague, tests inconclusive and ...

FAYETTEVILLE, GA, UNITED STATES, January 26, 2026 /EINPresswire.com/ -- Postoperative recurrence remains the main ...

Adding serum biomarkers to biannual ultrasound in patients at high risk for hepatocellular carcinoma may not improve the early detection of the condition.

Researchers assess the cost‐effectiveness of nivolumab plus ipilimumab vs lenvatinib or sorafenib for hepatocellular carcinoma from a US healthcare payer perspective.

Clinicians in 5 states participated in an online survey to gauge the level of compliance with HCC surveillance guidelines. According to the survey, knowledge gaps and barriers to HCC screening in ...

Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...

Despite demonstrating a significant survival advantage in the first-line treatment of unresectable hepatocellular carcinoma (HCC), the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is ...

Effect of the combination of systemic and locoregional therapy on tumor recurrence and survival after liver transplantation for hepatocellular carcinoma (HCC). This is an ASCO Meeting Abstract from ...